Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology... Ipsen S.A. is a French biopharmaceutical company headquartered in Paris, specializing in the development and commercialization of transformative medicines across three core therapeutic areas: oncology, rare diseases, and neuroscience. Founded in 1929 by Dr. Henri Beaufour as a family business, it has evolved over nearly a century into a global mid-sized player with approximately 5,000 employees worldwide, maintaining an agile, entrepreneurial mindset while achieving broad reach—its products are registered in 88 countries and directly commercialized in over 30. Ipsen pioneered key innovations like Decapeptyl for hormone-influenced conditions such as prostate cancer, Dysport for neurological disorders including dystonia and spasticity, Somatuline for acromegaly and neuroendocrine tumors, and more recent additions like cabozantinib for renal cell carcinoma, palovarotene for rare bone diseases, and Bylvay for pediatric rare liver conditions through strategic acquisitions. The company drives a robust pipeline via partnerships with biotechs and academia, targeting high unmet needs in cancers of the kidney, liver, and thyroid; rare genetic disorders; and debilitating neurological conditions, while emphasizing patient access, sustainability, and R&D hubs in France, the UK, and the US. Ipsen's science-led, patient-driven strategy underscores its role in advancing specialty care and fostering scientific exchange through the independent Fondation Ipsen.
In 2024, Ipsen was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Ipsen has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Ipsen are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Turnover
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Opex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Metric
2024
2023
2022
2021 - 2017
Total Taxonomy Aligned Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
Total Taxonomy Eligible Capex
0000000
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
4.1 CCM/CCA - Electricity generation using solar photovoltaic technology
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
4.16 CCM/CCA - Installation and operation of electric heat pumps
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
4.25 CCM/CCA - Production of heat/cool using waste heat
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
c
0000000
6.5 CCM/CCA - Transport by motorbikes, passenger cars and light commercial vehicles
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
b
Copy/Paste is a PRO feature.
c
0000000
7.1 CCM/CCA - Construction of new buildings
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
c
0000000
7.2 CCM/CCA - Renovation of existing buildings
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
c
0000000
7.3 CCM/CCA - Installation, maintenance and repair of energy efficiency equipment
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
c
0000000
7.4 CCM/CCA - Installation, maintenance and repair of charging stations for electric vehicles in buildings (and parking spaces attached to buildings)
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.5 CCM/CCA - Installation, maintenance and repair of instruments and devices for measuring, regulation and controlling energy performance of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.6 CCM/CCA - Installation, maintenance and repair of renewable energy technologies
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
7.7 CCM/CCA - Acquisition and ownership of buildings
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
c
0000000
Limited Data Preview
You are viewing a limited preview of Ipsen’s EU Taxonomy dataset. The full dataset, available for download, includes eligibility and alignment metrics for turnover, CAPEX, and OPEX across all EU Taxonomy categories, at both aggregate and activity level, with historical coverage back to 2021.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ipsen’s data sources below and access millions more through our Disclosure Search.
a. Ipsen's Universal Registration Document (URD) 2024
b. Ipsen's Universal Registration Document (URD) 2023
c. Ipsen's Universal Registration Document (URD) 2022
Insights into Ipsen's Revenues from Sustainable Activities
In 2024, Ipsen reported EU Taxonomy-eligible revenues of EUR 3.57 billion, representing 100% of its total turnover. Of this amount, EUR 0 of Ipsen's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Insights into Ipsen's CAPEX from Sustainable Activities
In 2024, Ipsen reported EU Taxonomy-eligible CAPEX of EUR 151.56 million,representing 76% of its total CAPEX. Of this amount, EUR 48.73 million of Ipsen's CAPEX was classified as EU Taxonomy-aligned, indicating that 24.4% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
Ipsen's Taxonomy-Eligible Capex Over Time
Total Taxonomy Eligible Capex
Total Taxonomy Aligned Capex
Have Ipsen's increased its investment in sustainable activities over time?
Compared to the previous year (2023), Ipsen's taxonomy-aligned CAPEX increased by 3,385.71%,highlighting Ipsen's strengthened commitment to investing in environmentally sustainable activities or improving how such investments are classified and reported under the EU Taxonomy.a, b
How much of Ipsen's capital expenditure (CAPEX) is eligible under the EU Taxonomy?
In 2024, Ipsen reported that EUR 151.56 million of its capital expenditure (CAPEX) was eligible under the EU Taxonomy, representing 76% of the company's total CAPEX. Of this amount, EUR 48.73 million (24.4% of total CAPEX) was classified as Taxonomy-aligned. This means that 51.6% of Ipsen's CAPEX is eligible but not aligned, indicating that these investments either did not meet the technical screening criteria, failed to comply with the Do No Significant Harm (DNSH) requirements, or lacked evidence of meeting the Minimum Safeguards (MSS).a
How much of Ipsen's eligible CAPEX is aligned with the EU Taxonomy?
In 2024, Ipsen reported that EUR 48.73 million of its CAPEX was aligned under the EU Taxonomy, representing 24.4% of its total capital investment.a
This moderate level of alignment indicates that Ipsen is beginning to transition its capital allocation toward greener investments, but still retains substantial opportunities for further alignment with sustainability goals.
Ipsen's Eligibility & Alignment Overview
Ipsen's Contribution to Environmental Objectives
Total Taxonomy Aligned Capex
How is Ipsen's taxonomy-aligned CAPEX distributed across the EU environmental objectives?
In 2024, Ipsen reported that its taxonomy-aligned capital expenditure (CAPEX) was distributed across the following EU environmental objectivesa:
Climate Change Mitigation: 24.4%
Climate Change Adaptation: 0%
Sustainable Use and Protection of Water and Marine Resources: 0%
Transition to a Circular Economy: 0%
Pollution Prevention and Control: 0%
Protection and restoration of biodiversity and ecosystems: 0%
How much Ipsen is investing in climate-related solutions?
In 2024, Ipsen allocated EUR 48.80 million of its CAPEX to activities contributing to the EU Taxonomy's climate-related objectives (Climate Change Mitigation and Climate Change Adaptation). This represented 24.4% of the company's total capital expenditure,indicating that Ipsenis moderately allocating capital toward climate-aligned initiatives, while maintaining a diversified investment portfolio.a
Insights into Ipsen's OPEX from Sustainable Activities
In 2024, Ipsen reported EU Taxonomy-eligible OPEX of EUR 689.70 million,representing 97.4% of its total operating expenses (OPEX). Of this amount, EUR 0 of Ipsen's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).a
b
b
b
c
b
c
b
c
a
c
a
c
c
a
a
c